A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Trial Profile

A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Diphencyprone (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 06 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to an RXi Pharmaceuticals Corporation media release.
    • 11 May 2017 According to a RXi Pharmaceuticals media release, the company expects early read-outs in the second half of 2017.
    • 13 Dec 2016 According to a RXi Pharmaceuticals media release, the read-out of the first cohort data will happen in the first half of 2017, the complete readout of the final study is anticipated in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top